Regeneron beats quarterly estimates on strong demand for Dupixent

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending its shares ... ...